AMRX
Price
$14.25
Change
+$3.96 (+38.48%)
Updated
Feb 3 closing price
Capitalization
4.48B
23 days until earnings call
Intraday BUY SELL Signals
BHC
Price
$5.70
Change
-$0.69 (-10.80%)
Updated
Feb 3 closing price
Capitalization
2.11B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRX vs BHC

Header iconAMRX vs BHC Comparison
Open Charts AMRX vs BHCBanner chart's image
Amneal Pharmaceuticals
Price$14.25
Change+$3.96 (+38.48%)
Volume$2.68M
Capitalization4.48B
Bausch Health Companies
Price$5.70
Change-$0.69 (-10.80%)
Volume$1.41M
Capitalization2.11B
AMRX vs BHC Comparison Chart in %
View a ticker or compare two or three
VS
AMRX vs. BHC commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Buy and BHC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (AMRX: $14.25 vs. BHC: $5.70)
Brand notoriety: AMRX: Not notable vs. BHC: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 99% vs. BHC: 57%
Market capitalization -- AMRX: $4.48B vs. BHC: $2.11B
AMRX [@Pharmaceuticals: Generic] is valued at $4.48B. BHC’s [@Pharmaceuticals: Generic] market capitalization is $2.11B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.79B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileBHC’s FA Score has 0 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • BHC’s FA Score: 0 green, 5 red.
According to our system of comparison, AMRX is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 3 TA indicator(s) are bullish while BHC’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 3 bullish, 4 bearish.
  • BHC’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BHC is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +3.04% price change this week, while BHC (@Pharmaceuticals: Generic) price change was -0.35% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.87%. For the same industry, the average monthly price growth was -0.69%, and the average quarterly price growth was +14.10%.

Reported Earning Dates

AMRX is expected to report earnings on Feb 27, 2026.

BHC is expected to report earnings on Feb 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.87% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($4.48B) has a higher market cap than BHC($2.11B). AMRX has higher P/E ratio than BHC: AMRX (1425.50) vs BHC (5.88). AMRX YTD gains are higher at: 13.095 vs. BHC (-17.986). BHC has higher annual earnings (EBITDA): 3.29B vs. AMRX (556M). BHC has more cash in the bank: 1.31B vs. AMRX (201M). AMRX has less debt than BHC: AMRX (2.69B) vs BHC (21B). BHC has higher revenues than AMRX: BHC (10B) vs AMRX (2.94B).
AMRXBHCAMRX / BHC
Capitalization4.48B2.11B213%
EBITDA556M3.29B17%
Gain YTD13.095-17.986-73%
P/E Ratio1425.505.8824,259%
Revenue2.94B10B29%
Total Cash201M1.31B15%
Total Debt2.69B21B13%
FUNDAMENTALS RATINGS
AMRX vs BHC: Fundamental Ratings
AMRX
BHC
OUTLOOK RATING
1..100
2757
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
34100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3982
P/E GROWTH RATING
1..100
1199
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHC's Valuation (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for AMRX (100) in the Pharmaceuticals Major industry. This means that BHC’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (34) in the Pharmaceuticals Major industry is significantly better than the same rating for BHC (100) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew significantly faster than BHC’s over the last 12 months.

AMRX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew similarly to BHC’s over the last 12 months.

AMRX's Price Growth Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for BHC (82) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew somewhat faster than BHC’s over the last 12 months.

AMRX's P/E Growth Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BHC (99) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew significantly faster than BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXBHC
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 13 days ago
72%
Bearish Trend 7 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signal:
Gain/Loss:
BHC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSIQX23.040.21
+0.92%
Goldman Sachs GQG Ptnrs Intl Opps R
ROFIX18.140.06
+0.33%
Royce Small-Cap Opportunity Instl
NSMRX37.170.09
+0.24%
Nuveen Small/Mid-Cap Value I
FTZCX65.02-0.22
-0.34%
FullerThaler Behvrll Uncnstd Eq C
POLIX32.48-1.31
-3.88%
Polen Growth Institutional

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with VTRS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+0.42%
VTRS - AMRX
51%
Loosely correlated
N/A
AMPH - AMRX
46%
Loosely correlated
+1.15%
TEVA - AMRX
44%
Loosely correlated
+2.06%
PAHC - AMRX
40%
Loosely correlated
-1.43%
BHC - AMRX
38%
Loosely correlated
-1.04%
More

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
-1.04%
AMRX - BHC
39%
Loosely correlated
+0.42%
COLL - BHC
29%
Poorly correlated
+0.85%
HROW - BHC
29%
Poorly correlated
+5.10%
AMPH - BHC
27%
Poorly correlated
+1.15%
NBIX - BHC
26%
Poorly correlated
+0.98%
More